Can You Take Abiraterone and Spironolactone Together?

No. According to the documented source record, abiraterone and spironolactone should not be used together. The combination is classified as contraindicated, meaning the risks outweigh potential benefits for concurrent use in prostate cancer patients. Spironolactone may interfere with how abiraterone works and could increase prostate-specific antigen (PSA) levels in treated patients.

What the Source Says

The interaction record for abiraterone and spironolactone carries a contraindicated severity rating. This is the highest level of concern—more restrictive than "major" or "moderate"—and signals that concurrent use is not recommended by documented evidence.

The description in the source record is specific: "Spironolactone binds to androgen receptor and may increase PSA levels in abiraterone-treated prostate cancer patients. Concomitant use not recommended."

The documented mechanism is listed as "androgen receptor binding interference." This source material comes from NLP (natural language processing) analysis of spironolactone labeling information. The record was most recently updated on May 4, 2026.

Because this is a contraindicated pairing, it is not a situation in which dose adjustment, monitoring, or timing changes can safely resolve the concern. Instead, the medical evidence indicates the combination itself should be avoided.

How to Understand This Interaction

To appreciate why this pairing is problematic, it helps to know what each drug does and where they interfere.

What abiraterone does: Abiraterone is a CYP17 inhibitor, a medication used to treat metastatic castration-resistant prostate cancer (mCRPC). It works by blocking an enzyme called CYP17A1, which is involved in testosterone synthesis. By lowering testosterone production, abiraterone slows prostate cancer growth. Patients on abiraterone are monitored closely via PSA (prostate-specific antigen) blood tests, because PSA levels serve as a clinical marker of cancer progression or treatment response. A rising PSA during abiraterone therapy suggests the cancer is becoming resistant to the drug.

What spironolactone does: Spironolactone is a potassium-sparing diuretic and aldosterone antagonist commonly used to manage fluid retention, hypertension, and heart failure. It also has activity at the androgen receptor—the cellular target that male hormones (androgens) bind to in order to exert their effects. This androgen receptor activity is an off-target property of spironolactone, not its primary intended mechanism, but it is clinically significant.

How they interfere: The documented mechanism is "androgen receptor binding interference." The source record indicates that spironolactone's binding to the androgen receptor may increase PSA levels in patients being treated with abiraterone. This creates two problems:

• Androgen receptor signaling may counteract or reduce the effectiveness of abiraterone's hormonal suppression strategy.
• Rising PSA levels in a patient on abiraterone suggest treatment failure or cancer progression, making clinical interpretation of response difficult and potentially delaying recognition that a change in therapy is needed.

The source record does not provide detailed pharmacokinetic data (such as whether spironolactone alters abiraterone's blood levels), nor does it cite a specific incidence rate or magnitude of PSA elevation. The mechanism described—androgen receptor interference—is the documented basis for concern.

Important distinction: General pharmacology education teaches that spironolactone has some androgen receptor activity and that inhibiting CYP17 reduces androgen production. It might seem logical that these could interfere. However, this article is based on a specific documented interaction record, not on theoretical reasoning alone. The source material explicitly identifies this pair as contraindicated, which means clinical evidence or expert consensus has established the actual risk in patients.

Who Should Pay Particular Attention

Patients with metastatic castration-resistant prostate cancer who are prescribed abiraterone should be aware of this contraindication. If you have hypertension, heart failure, or another condition for which spironolactone might typically be considered, your prescribing team needs to know you are on abiraterone so they can choose an alternative diuretic or blood-pressure medication.

Caregivers and family members of patients on abiraterone should also be aware: if a new prescription for spironolactone is being considered, raise this documented interaction promptly with the patient's oncologist or pharmacist.

Pharmacists reviewing medication lists should flag this pairing whenever both drugs appear, even if they were prescribed at different times by different specialists. Abiraterone is an oncology medication, and spironolactone is often prescribed in cardiology or nephrology, so the prescribers may not be coordinating.

Hypothetical Examples

Scenario 1 (documented concern): A patient with metastatic prostate cancer is on abiraterone therapy. His PSA has been stable for six months, suggesting the drug is working. His cardiologist, unaware of the abiraterone use, prescribes spironolactone for management of heart failure and reduced ejection fraction. After six weeks on spironolactone, the patient's PSA rises significantly at his next oncology visit. The oncology team must now determine whether this rise represents cancer progression requiring a change in prostate cancer therapy, or whether it is an artifact of the new spironolactone. Meanwhile, treatment decisions are complicated, and the patient may receive additional or unnecessary interventions. This scenario illustrates why the documented contraindication exists: spironolactone interferes with PSA interpretation and potentially with abiraterone's mechanism of action.

Scenario 2 (prevention through communication): A patient on abiraterone develops peripheral edema and mild hypertension. His primary care physician considers prescribing spironolactone but first checks the patient's medication list and sees abiraterone. The physician contacts the oncology team to discuss the documented contraindication. Together, they choose an alternative agent—perhaps a loop diuretic for edema and an ACE inhibitor or calcium-channel blocker for blood pressure—that does not interact with abiraterone. The patient's cancer therapy remains on track, and his volume status and blood pressure are managed safely. This scenario shows how awareness of the contraindication prevents harm.

What to Discuss With a Pharmacist or Physician

If you are taking abiraterone and spironolactone has been prescribed (or is being considered), here are questions and points to raise:

• "I am on abiraterone for prostate cancer. I see spironolactone in my medication list. Is this combination safe?" This direct question prompts your pharmacist or doctor to review the documented contraindication and explain the specific risk to you.
• "Why is spironolactone contraindicated with abiraterone?" Asking for the reason helps you understand that the concern is not arbitrary—it relates to androgen receptor interference and PSA interpretation in your cancer therapy.
• "What are alternatives to spironolactone for my heart failure [or hypertension, or edema]?" If spironolactone was chosen for a non-cancer reason, other agents are available. Your prescriber can select one that does not interfere with abiraterone.
• "How will my PSA be monitored if I've been on spironolactone?" If you have been taking spironolactone and abiraterone together, your oncology and cardiology teams should be aware and should discuss whether PSA trends have been affected.
• "Should my spironolactone be stopped before I start abiraterone?" If you are beginning abiraterone and are already on spironolactone, clarify the timeline for any medication changes with your care team.

Do not stop, start, or change any medication on your own. These questions are meant to facilitate a conversation with your healthcare providers so that they can make safe, informed decisions tailored to your complete medical picture.

Key Takeaways

• Abiraterone and spironolactone are classified as contraindicated—meaning they should not be used together—according to documented source material.
• Spironolactone binds to the androgen receptor, which may interfere with abiraterone's therapeutic effect and increase PSA levels in prostate cancer patients being treated with abiraterone.
• PSA is a key clinical marker for assessing abiraterone response; interference from spironolactone makes it difficult to interpret whether the cancer therapy is working.
• If you are on abiraterone and need treatment for heart failure, hypertension, or edema, alternative medications are available that do not carry this documented interaction.
• Always inform all of your doctors and pharmacists that you are on abiraterone, especially when new medications are being prescribed, because it may not appear in every clinical specialist's routine review.

Sources

• DailyMed (NIH/NLM) – Authoritative source for FDA-approved drug labeling and medication information.
• FDA Open Data Portal – Public access to FDA adverse event reports, drug approvals, and labeling updates.
• RxNorm (NIH/NLM) – Standardized naming and classification of clinical drugs and drug interactions.

If you are taking abiraterone, spironolactone, or both, visit checkdruginteractions.com to review your complete medication list for documented interactions. Always confirm any medication changes, questions about side effects, or concerns about your therapy with your pharmacist or physician. They have access to your full medical history and can provide personalized guidance that an educational resource cannot.